Generation of BA.2 mAbs
(A) Sorting of BA.2-specific B cells.
(B) Proportion of BA.2 mAbs binding to RBD.
(C) ACE2 receptor blocking activity of mAbs.
(D) Gene usage in 25 potent BA.2 mAbs compared with potent antibodies produced following infection with early-pandemic virus, which have been previously reported.4
(E) Number of somatic mutations found in BA.2 mAbs compared with sets previously recovered from early-pandemic, Beta, and Omicron (BA.1) infections, which have been reported previously.4,13,14